Blueprint Medicines Corp (NASDAQ: BPMC)’s stock price has increased by 1.96 compared to its previous closing price of 101.57. However, the company has seen a -6.17% decrease in its stock price over the last five trading sessions. zacks.com reported 2025-02-06 that Blueprint Medicines (BPMC) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is It Worth Investing in Blueprint Medicines Corp (NASDAQ: BPMC) Right Now?
The 36-month beta value for BPMC is at 0.55. Analysts have varying views on the stock, with 9 analysts rating it as a “buy,” 5 rating it as “overweight,” 5 as “hold,” and 1 as “sell.”
The public float for BPMC is 62.04M, and currently, shorts hold a 6.79% of that float. The average trading volume for BPMC on February 13, 2025 was 769.79K shares.
BPMC’s Market Performance
The stock of Blueprint Medicines Corp (BPMC) has seen a -6.17% decrease in the past week, with a 0.19% rise in the past month, and a 2.71% gain in the past quarter. The volatility ratio for the week is 4.57%, and the volatility levels for the past 30 days are at 3.73% for BPMC. The simple moving average for the past 20 days is -5.89% for BPMC’s stock, with a 4.86% simple moving average for the past 200 days.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with JP Morgan repeating the rating for BPMC by listing it as a “Overweight.” The predicted price for BPMC in the upcoming period, according to JP Morgan is $126 based on the research report published on November 14, 2024 of the previous year 2024.
UBS, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $88. The rating they have provided for BPMC stocks is “Neutral” according to the report published on October 24th, 2024.
Stephens gave a rating of “Overweight” to BPMC, setting the target price at $140 in the report published on May 14th of the previous year.
BPMC Trading at 3.75% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -15.05% of loss for the given period.
Volatility was left at 3.73%, however, over the last 30 days, the volatility rate increased by 4.57%, as shares surge +0.98% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.90% upper at present.
During the last 5 trading sessions, BPMC fell by -6.17%, which changed the moving average for the period of 200-days by +14.14% in comparison to the 20-day moving average, which settled at $110.04. In addition, Blueprint Medicines Corp saw 18.73% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Haviland Kate, who sale 1,446 shares at the price of $110.24 back on Jan 21 ’25. After this action, Haviland Kate now owns 149,378 shares of Blueprint Medicines Corp, valued at $159,407 using the latest closing price.
Rossi Christina, the CHIEF OPERATING OFFICER of Blueprint Medicines Corp, sale 2,274 shares at $110.14 during a trade that took place back on Jan 21 ’25, which means that Rossi Christina is holding 67,109 shares at $250,455 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.64 for the present operating margin
- 0.95 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.29. The total capital return value is set at -0.29. Equity return is now at value -49.66, with -11.11 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.6 points at debt to capital in total, while cash flow to debt ratio is standing at -0.51. The debt to equity ratio resting at 1.51. The interest coverage ratio of the stock is -4.2.
Currently, EBITDA for the company is -470.36 million with net debt to EBITDA at -1.59. When we switch over and look at the enterprise to sales, we see a ratio of 16.02. The receivables turnover for the company is 6.6for trailing twelve months and the total asset turnover is 0.36. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.32.
Conclusion
In conclusion, Blueprint Medicines Corp (BPMC) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
